Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
56
resultados
Última actualización
21/07/2025 [06:45:00]
Resultados 50 a 56 de 56
Resumen de: TW202440945A
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
Resumen de: WO2025132479A1
The role of pro- and anti-inflammatory macrophages in disease depends on the specific disease and the balance between the two types of macrophages. Imbalances can lead to the development or progression of diseases, and targeting macrophage function may be a potential therapeutic approach for certain diseases. For example, by altering the phenotype and function of TAM-M2, it is possible to shift the immune response from an anti-inflammatory to a pro-inflammatory state, which may help reduce tumor progression. Here, the inventors demonstrate the ability of Gilteritinib to reprogram primary human macrophages. Gilteritinib is a targeted therapy used in the treatment of acute myeloid leukemia (AML) with a specific genetic mutation called FLT3-internal tandem duplication (FLT3-ITD) or a tyrosine kinase domain (TKD) mutation. Accordingly, the present invention relates to an FLT3 inhibitor to modulate the immune environment and enhance existing therapies by blocking immunosuppressive immune cells.
Resumen de: WO2025137567A1
Some embodiments of the disclosure include compounds of Formula (I) and Formula (la), and compositions thereof, e.g., pharmaceutical compositions, which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the compounds (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Resumen de: US2025205309A1
The disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a combination of a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion, such as XmAb24306, and a FcRH5xCD3 bispecific antibody, such as cevostamab.
Resumen de: WO2025137368A1
A myelodysplastic syndrome-related detection system obtains single-nucleus or single-cell transcriptome data for genes for each of a plurality of nuclei or cells. Each nucleus or cell is obtained from a sample from a different subject in a cohort. Metadata for each respective subject is obtained that indicates whether the respective subject has myelodysplastic syndrome or is healthy. The nuclei or cells are clustered into clusters by computing distances using the transcriptome data for the genes for each unique pair of nuclei or cells in the plurality of nuclei or cells and through evaluation of these distances with a criterion function. Each cluster has a subset of nuclei or cells. The metadata identifies a cluster associated with the myelodysplastic syndrome on the basis that the cluster is enriched for nuclei or cells from subjects having the myelodysplastic syndrome.
Nº publicación: US2025207202A1 26/06/2025
Solicitante:
OHIO STATE INNOVATION FOUND [US]
Ohio State Innovation Foundation
Resumen de: US2025207202A1
The present disclosure provides kits and/or methods of detecting and identifying epigenetic patterns associated with acute myeloid leukemia and other cancers. The present disclosure also relates to treating, preventing, ameliorating, or reducing acute myeloid leukemia and other cancers.
BOPI
Sede Electrónica
